DGAP-News: HAEMATO AG
/ Key word(s): Quarter Results/Quarterly / Interim Statement
31.05.2021 / 08:37
The issuer is solely responsible for the content of this announcement.
Corporate News of HAEMATO AG:
HAEMATO AG with strong start to the year: EBIT rises in Q1 by 350 % to EUR 2.4 million and revenues by 22 % to EUR 73.9 million.
Berlin, 31.05.2021 – HAEMATO AG (ISIN: DE000289VV1), has continued its growth course in the first months of 2021. Due to a strong core business, consolidated sales (IFRS) increased by 22 % to EUR 73.9 million in the first quarter of 2021. The specialist in drugs for the treatment of chronic diseases and for individual therapies increased earnings disproportionately at all levels. The result from ordinary activities (EBITDA) rose by 196 % to EUR 2,823 thousand (previous year: EUR 954 thousand) and the operating result (EBIT) by 350% to EUR 2,428 thousand. Thus, after the first three months of the current year, EBIT already exceeds the figure for 2020 as a whole. One reason for the increase in earnings is the improvement in the gross margin, which has increased from 7.2 % (previous year) to 9.8 % in the first quarter of 2021.
“HAEMATO has streamlined its product portfolio in recent years and consistently focused on high-margin areas with sustainable growth potential. This is paying off more and more,” says HAEMATO CEO Patrick Brenske. “Today, our growth drivers are special pharmaceuticals against chronic diseases and products around aesthetic medicine. For medical cannabis, demand clearly exceeds our supply and we are currently looking for additional suppliers.”
At the end of March 2021, the subsidiary HAEMATO PHARM GmbH received special approval from the Federal Institute for Drugs and Medical Devices (BfArM) for a Covid 19 antigen rapid test for self-testing by laypersons. In April and May 2021, a sales volume of almost EUR 25 million was already generated with the medical products from the “Diagnostics” segment, which will be positively reflected in the business figures for the second quarter of 2021. Medium-term demand for Covid 19 rapid tests depends largely on the further course of the pandemic, the vaccination rate and the national testing strategy in Germany.
Due to the still ongoing Corona pandemic, HAEMATO AG will again make use of the option to invite shareholders to the company’s Annual General Meeting scheduled for 13 July 2021 with a shortened notice period of 21 days.
HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of its business activities is on the trading of high-priced special pharmaceuticals (with a therapeutic focus on cancer, HIV, and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the field of “aesthetic medicine”. HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information at: www.haemato.ag.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 (0)30 897 30 86 70|
|Fax:||+49 (0)30 897 30 86 79|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange|
|EQS News ID:||1202340|
|End of News||DGAP News Service|